New $475M credit lines expiring in 2030 enable APLS to pay off debt due in 2027.
APLS’ Syfovre is not an especially good drug (#msg-173940338), but there is apparently no shortage of lenders to refinance debt of companies with FDA-approved products.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”